Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.49.5
PrivacidadTérminosCookiesAviso Legal
● Connected
INSM US Equity
INSMED Inc
99.66USD▼ 0.82%
Healthcare
Biotechnology
96)Comparar97)Tesis →
Market Cap
$21.8B
Shares Outstanding
218M
— Annual —FY2025
Revenue
$606M
Gross Margin
79.7%
Operating Margin
-205.6%
Net Margin
-210.5%
FCF Margin
-159.6%
ROE
-172.8%
ROCE
-69.4%
Net Debt/EBITDA
-0.0×
Current Ratio
3.83
D/E Ratio
0.74
FCF / Share
-4.43
Book Value / Share
3.38
INSM US Equity
99.66USD▼ 0.82%
Tesis →

INSMED Inc (INSM): análisis fundamental y valoración

INSMED Inc cotiza a 99.66 USD y tiene una capitalización bursátil de $21.8B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaNasdaqPaísUnited StatesEmpleados1,664Beta0.82Web↗ www.insmed.com

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatm…

Múltiplos de Valoración
P/E (Annual)
—
P/E (TTM)
—
P/FCF (Annual)
—
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
36.0×
P/Sales
35.9×
P/Book
29.4×
Rentabilidad (Último Anual)
Gross Margin
79.7%
Operating Margin
-205.6%
Net Margin
-210.5%
FCF Margin
-159.6%
ROE
-172.8%
ROCE
-69.4%
ROA
-56.4%
Effective Tax Rate
—
Métricas TTM
Revenue TTM
—
Gross Profit TTM
—
Operating Income TTM
—
Net Income TTM
—
FCF TTM
—
EPS TTM
—
Quarters Used
—
TTM Period
—
Solidez del Balance
Net Debt
$36M
Net Debt / EBITDA
-0.0×
Debt / Equity
0.74
Current Ratio
3.83
Interest Coverage
-14.9×
Working Capital
$1.3B
Book Value / Share
3.38
Net Debt / Share
0.17
Crecimiento (YoY)
Revenue YoY
+66.7%
Net Income YoY
-39.7%
FCF YoY
-37.1%
EPS Diluted YoY
-15.3%
Retorno al Accionista
Dividend Yield
—
Payout Ratio
—
FCF / Share
-4.43
CapEx % Revenue
5.4%
Rev / Employee
364,436
Próximos Eventos
Historial EPS
Periodo2026-102026-082026-052026-02
Real—$-0.06$-0.76$-1.54
Estimado$-0.37$-0.68$-1.00$-1.17
Sorpresa—+91.2%+24.0%-31.6%
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaINSMMediana SectorΔ
Gross Margin79.7%57.0%+22.7%
Operating Margin-205.6%-38.6%-167.0%
Net Margin-210.5%-33.6%-177.0%
FCF Margin-159.6%-13.9%-145.7%
ROE-172.8%-40.4%-132.4%
ROA-56.4%-32.0%-24.4%
Current Ratio3.832.84+0.99
Debt / Equity0.740.28+0.46
Scoring Fundamental
Piotroski F-Score
4/ 9Débil
✗F1ROA positivo (rentabilidad activos)
✗F2Flujo caja operativo positivo
✗F3ROA mejora vs año anterior
✓F4Calidad de beneficios (OCF > ROA)
✓F5Apalancamiento baja
✗F6Liquidez mejora (current ratio)
✗F7Sin dilución accionarial
✓F8Margen bruto mejora
✓F9Rotación activos mejora
Altman Z-ScoreZona Segura
4.30
x1_working_capital0.585
x2_retained_earnings-2.489
x3_ebit-0.551
x4_market_equity14.383
x5_sales0.268
>2.99 segura · 1.81–2.99 gris · <1.81 riesgo
Capital Allocation
4/ 8Moderada
✗FCF+Free cash flow positivo
✗FCFmMargen FCF > 10%
✗DilucSin dilución significativa (< 2%/año en 3 años)
✓Rev↑Revenue CAGR 3 años > 5%
✗ROCERetorno sobre capital empleado > 10%
✓DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✓Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✓Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)
Histórico Piotroski F-Score
Histórico de Múltiplos